New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for...(t change on thescale (as calculated from...),Health

On the CGI-I scale, clinicians rated 83 percent of boys and girls "improved" or "very much improved" at the end of the study compared to week one. Additionally, the PGA rating scale showed that 78 percent of boys and girls "improved" or "very much improved" at the end of the study compared to week one. The results in both the CGI-I and PGA scale were comparable between boys and girls.

Dr. Findling added, "These positive findings, along with previously presented research, reinforces that the ADHD patch is an important treatment option for children, especially those who may benefit from an ADHD medication that can accommodate their changing daily needs."

DAYTRANA is the first and only non-oral medication for treating ADHD in children aged 6 to 12 years. Parents can adjust the wear time up to 9 hours under the physician's advice to accommodate for their child's varying weekdays, weekend and vacation schedules. DAYTRANA is available in four dosage strengths -- 10 mg, 15 mg, 20 mg and 30 mg -- all designed for once-daily use.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

This analysis was supported by Shire Development Inc.

Additional information about DAYTRANA and Full Prescribing Information are available at http://www.DAYTRANA.com.

Note to Editors:

ADHD-RS-IV assesses 18 individual symptoms of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revis
'/>"/>